The subcutaneous biologics market size is calculated at USD 2.1 billion in 2025 and is expected to reach around USD 5.37 ...

Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...

Viking Therapeutics, Inc. progressing rapidly with its Phase 3 VANQUISH trials of VK2735 set to complete enrolment. Learn ...

Eli Lilly ( LLY 0.76%) has been on a tear for the better part of the last decade, but the company has experienced a bit of a ...

J&J announces Tremfya, the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years: Phoenix Tues ...

Claire, a 9-month-old Australian Cattle Dog, was severely burned after being left outside in extreme heat. Now healthy, she ...

Dr Elise Dallas, a GP at London General Practice, has explored six common reasons why individuals tend to feel the cold more ...

Both stocks look attractively valued relative to their growth potential. There are plenty of attractive stocks on the market.

Indianapolis: Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved a ...

Chronic conditions such as hypothyroidism, anaemia and diabetes can all increase sensitivity to cold in older adults by ...

The intervention being tested is a drug named PF-06741086, also known as marstacimab. It is administered as a subcutaneous injection and is intended to serve as a prophylactic treatment to prevent ...

BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...